Nippon Shinyaku and Shionogi are filing for new drugs. Beigene dropped a phase 3 oncology asset. Mesoblast is about to start treatment with Ryoncil. Lupin is acquiring UK-based Renascience Pharma.
What is covered in the Full Insight:
Nippon Shinyaku NDA Submission
Shionogi FDA Rolling NDA for Xocova
BeiGene Ociperlimab Update
Celltrion CHMP Opinion for Omlyclo
Pharmaceutical Sector and Tariffs Impact
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.